There are many funding opportunities that support the conduct of rigorous, cutting-edge dissemination and implementation research at the National Cancer Institute (NCI) and across the National Institutes of Health (NIH). The most prominent funding opportunity is the Trans-NIH program announcement with special receipt, referral and/or review (PAR), Dissemination and Implementation Research in Health (DIRH). NCI, along with many other participating institutes and centers across NIH, issued this PAR for R01, R21, and/or R03 funding sources. Learn more about this implementation science (IS) funding opportunity and find resources for prospective IS applicants.
Coronavirus Disease 2019 (COVID-19): Information about NIH and NCI Funding
NIH has compiled a continuously evolving list of available resources pertaining to the COVID-19 public health emergency with links to the NIH Guide Notices and FAQs. See information for NIH applicants and funding recipients.
View NCI Bottom Line Blog post on NCI funding during the COVID-19 public health emergency.
Funding Announcements
Trans-NIH PAR, Dissemination and Implementation Research in Health
Successful Grant Applications
View excerpts from successfully funded research grant applications to help prepare applications for NCI funding.
Sample Grant ApplicationsFunding Inquiry Staff Contact
Gila Neta, PhD, MPP
Program Director
gila.neta@nih.gov
Clinical Trials & Implementation Science
NIH Clinical Trial Policies
In 2016, NIH launched a multi-faceted effort to enhance its stewardship over clinical trials. The goal of this effort is to encourage advances in the design, conduct, and oversight of clinical trials while elevating the entire biomedical research enterprise to a new level of transparency and accountability. The NIH definition of a clinical trial was revised in 2014 in anticipation of these stewardship reforms to ensure a clear and responsive definition of a clinical trial. If you need assistance determining whether your proposed study is a clinical trial, visit the NIH Office of Extramural Research clinical trial website.
What is a Clinical Trial?
The NIH definition of a clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
Clinical Trial-Specific Funding Opportunities
NIH requires that all applications involving one or more clinical trials be submitted through a Funding Opportunity Announcement (FOA) specifically designed for clinical trials. The purpose of this policy is to improve our ability to identify proposed clinical trials, ensure that key pieces of trial-specific information are submitted with each application, and uniformly apply trial-specific review criteria. FOAs are classified as Clinical Trial Optional, Clinical Trial Required, or Clinical Trial Not Allowed.
More Prospective Grantee Resources
Learn about NCI’s participation in the set of NIH announcements, “Dissemination and Implementation Research in Health (R01/R21 - Clinical Trial Optional, R03 – Clinical Trial Not Allowed).
WebinarThe Science of Implementation in Health and Healthcare (SIHH) Study Section reviews applications that identify, develop, and evaluate dissemination and implementation theories, strategies and methods designed to integrate evidence-based health interventions into public health, clinical, and community settings. Applications reviewed in SIHH should have a major methods, strategy, or theoretical development component in implementation science in order to understand how interventions are implemented and measure implementation outcomes in public health, clinical, and community settings.
Membership and Meeting RostersIn 2015, IS team members published a portfolio analysis of dissemination and implementation grants funded by the NCI in cancer prevention and control between 2000 to 2012. The portfolio analysis identified 67 NCI grant awards with an implementation science focus. The R01 mechanism was the most common funding mechanism. Prevention grants were most common (49.3%) and cancer treatment grants were least (4.5%), with most grants including both quantitative and qualitative methods (69%).
Open-Access ArticleCurrent and previous grants funded through the DIRH FOA in cancer prevention and control by DCCPS are listed in a searchable table for reference.
Funded Grants